There were whispers in the marketplace that Bristol Myers-Squibb (NYSE:BMY) was still looking to beef up their pipeline in NASH but Dealreporter broke the news that the BMY’s business development chief Paul Biondi is “actively looking for acquisition or license opportunities in fibrotic diseases.” After this speculation broke out and buoyed the valuations of the some of the NASH players. Keep in mind this was on the heels of Madrigal’s (NASDAQ:MDGL) favorable clinical trial announcement. In this article we are going to explore BMY’s pipeline and possible acquisition candidates. Analysis is